Notice NOT-CA-20-096 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HD-21-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the novel development of Centers to Advance Research in Endometriosis (CARE). These multidisciplinary programs will incorporate basic, translational, and/or clinical studies (excluding clinical trials) in a collaborative entity to accelerate research advances through sharing of knowledge and resources. The ultimate goal of the program is to improve female reproductive health through successful prevention and treatment of endometriosis.

Funding Opportunity PAR-20-295 from the NIH Guide for Grants and Contracts. [The purpose of this PAR is to bring a highly sensitivity imaging technology capable of locating very small (1-3 mm) tumors in vivo to clinical utility. Under this funding opportunity, NCI solicits innovative concepts that propose a path to clinical validation for in vivo intelligent or activated optical fluorescence agents or probes with demonstrated capabilities for detection of small tumors. Current imaging techniques are in use for non-invasive cancer detection, but clinical methods are limited to detecting masses several millimeters to centimeters in size. To image small primary or metastatic tumor sites composed of 106 to 107 cells, imaging sensitivity must be improved. This can be achieved without significant hardware advances by improving the contrast between diseased and healthy tissue captured in the image. Thus, there is a clinical need for techniques that improve image contrast between tumors and surrounding background tissue. There are several novel optical fluorescence methods that rely on the use of specialized agents that are activated when coupled to a tumor target. These activated agents dramatically increase the contrast between small tumor cell masses and surrounding tissue. Efforts to develop activated fluorescence imaging agents have been ongoing for over a decade. These developmental successes now need to be translated for clinical use. This FOA thus supports translation of novel activated optical fluorescence technologies for sensitive cancer detection In Vivo. Clinical translation and validation are the primary goals of the proposed research. Minimal development activity in preparation for clinical validation will be accepted. The bulk of the proposed research must focus on translating improvements to imaging sensitivity to a clinical environment. The goal is to demonstrate that tumor cell aggregations on the order of 1 mm 3 in diameter can be visualized in vivo. This FOA, does not support continued development of novel technologies

Notice NOT-OD-20-161 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-TR-20-030 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites researchers to submit applications for multidisciplinary diagnostic strategies for rare diseases that combine machine-assistance, genomic analysis, and clinical consultation. Of particular importance, these strategies must be able to be adopted and performed at the primary or secondary care levels by front-line healthcare providers and be readily integrated into their clinical care workflow.

Notice NOT-OD-20-167 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-274 from the NIH Guide for Grants and Contracts. This funding opportunity announcement will support the development and testing of enhanced models of care that are able to optimally integrate HIV, addiction, and primary care services.

Funding Opportunity PAR-20-273 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services.

Notice NOT-OD-20-171 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-169 from the NIH Guide for Grants and Contracts

Notice NOT-GM-20-046 from the NIH Guide for Grants and Contracts

Notice NOT-TR-20-036 from the NIH Guide for Grants and Contracts

Notice NOT-MH-20-081 from the NIH Guide for Grants and Contracts

Notice NOT-MH-20-080 from the NIH Guide for Grants and Contracts

The successful applicant will collaborate with faculty across the state to develop curricula and training in bioinformatics skills with college and university… $55,000 a year
From University of Wyoming - Thu, 27 Aug 2020 14:14:42 GMT - View all Laramie, WY jobs

£60000 - £97000 per annum, Benefits: Bonus : Hyper Recruitment Solutions (HRS): We are currently looking for a Bioinformatician to join an exciting gene therapy company based in the London area where data is the heart of... London

Funding Opportunity RFA-CA-20-047 from the NIH Guide for Grants and Contracts. The overall goal of this funding opportunity announcement (FOA) is to improve the treatment of adult glioblastoma (GBM) by developing novel effective agents that can cross the blood-brain barrier (BBB) and testing them in the clinic. To implement this concept, multi-institution teams are invited to participate in the Glioblastoma Therapeutics Network (GTN). Each GTN team will be capable of driving therapeutic agent(s) from pre-clinical development, through IND studies, into pilot clinical studies in humans.

Funding Opportunity PAR-20-297 from the NIH Guide for Grants and Contracts. The National Institute for Occupational Safety and Health (NIOSH) plans to publish a funding opportunity announcement (FOA) for NIOSH Centers of Excellence for Total Worker Health. The NIOSH Centers of Excellence for Total Worker Health advance the overall safety, health, and well-being of the diverse population of workers in our nation.

Notice NOT-DK-20-047 from the NIH Guide for Grants and Contracts

Notice NOT-NS-21-001 from the NIH Guide for Grants and Contracts